title: The clinical behavior of localized and multicentric Castleman disease.
abstract: BACKGROUND
  Castleman disease, an unusual condition of unknown cause consisting of a massive proliferation of lymphoid tissue, remains a clinicopathologic diagnosis. Three histologic variants (hyaline vascular, plasma-cell, and mixed) and two clinical types (localized and multicentric) of Castleman disease have been described.
  
  
  OBJECTIVE
  To analyze the clinical features, management, and outcome of patients with Castleman disease.
  
  
  METHODS
  Case series.
  
  
  METHODS
  University referral hospitals.
  
  
  METHODS
  All patients with Castleman disease who were seen at Texas Medical Center, Houston, Texas, between 1977 and 1995.
  
  
  METHODS
  Surgical excision for localized disease; surgery, combination chemotherapy, or prednisone for multicentric disease.
  
  
  METHODS
  Patients were identified according to initial presentation as having localized or multicentric Castleman disease. Patients within each group were further subdivided according to whether they had hyaline vascular, plasma-cell, or mixed disease.
  
  
  RESULTS
  Data from 15 patients were analyzed. All 7 patients with localized disease underwent surgical excision and remain free of disease. The 8 patients with multicentric disease were further subdivided according to initial treatment: Three patients who received combination chemotherapy are currently alive and free of disease; 2 patients treated with prednisone are alive but have needed intermittent maintenance therapy for disease reactivations; and 2 patients treated with surgery only have died, 1 of infectious complications and 1 of non-Hodgkin lymphoma.
  
  
  CONCLUSIONS
  Localized and multicentric Castleman disease are different clinical disorders with overlapping histologic features. Localized disease can be cured with surgery, but complete remissions in patients with multicentric disease have been achieved only with chemotherapy or prednisone given at the time of diagnosis.
authors.affiliation: University of Texas M.D. Anderson Cancer Center, Baylor College of Medicine, and Methodist Hospital, Houston 77030, USA.
authors.forename: J
authors.initials: J
authors.lastname: Herrada
authors.forename: F
authors.initials: F
authors.lastname: Cabanillas
authors.forename: L
authors.initials: L
authors.lastname: Rice
authors.forename: J
authors.initials: J
authors.lastname: Manning
authors.forename: W
authors.initials: W
authors.lastname: Pugh
mesh_terms: D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D005871:Castleman Disease / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone